RT Journal Article
SR Electronic
T1 Endobronchial photodynamic therapy with chlorine E6 in III-IV stage central lung cancer
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p622
VO 38
IS Suppl 55
A1 Valentina Molodtsova
A1 Nikita Kazakov
A1 Anatoly Rusanov
A1 Ivan Chistiakov
A1 Margarita Urtenova
A1 Yulia Kulakova
A1 Andrey Akopov
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p622.abstract
AB Aim: To evaluate short- and long- term results of photodynamic therapy (PDT) with chlorine e6 in palliative treatment of lung cancer.Methods: 52 patients with IIIb (21) and IV (31) stage of lung cancer with major airway obstruction were prospectively included in endobronchial PDT protocol. Histological types were: NSCLC – 46 patients, SCLC – 6 patients. Water-soluble chlorine e6 complex was used as a photosensitizer in dose of 2 mg/kg. The interval between the injection and illumination was 2 hours. Red light at 662+1 nm wavelength was used to achieve a total illumination dose of 250 j/cm2 of the tumor during flexible bronchoscopy under topical anaesthesia. All patients except four received chemotherapy concomitantly. PDT was done twice in 13, three and more times – in 39 patients. Results of treatment were evaluated by percentage of bronchial lumen desobliteration in every four weeks after the first procedure. Survival was calculated using Kaplan-Meier method.Results: Bronchial desobliteration after the first PDT was recorded as complete endobronchial remission – in 17 cases (33%), partial (>50% of tumor volume) – in 21 cases (42%). No effect was seen in 25% of patients. After the next procedures number of patients with complete remission decreased to 24%, patients with partial remission - increased up to 53%. Median survival time was 11,6 months, it was higher in patients with complete remission than with partial remission (13,5 vs 10,3 months, p<0,05). One year survival was 48%, two years survival - 24%.Conclusion: Repeated PDT with chlorine e6 is a safe and effective for lung cancer patients. Survival depends on degree of endobronchial remission.